TrialSignal transduction and targeted therapy2024

Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432).

Xinghao Ai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.